Navigation Links
JDRF-Helmsley Charitable Trust to fund islet encapsulation research at Diabetes Research Institute
Date:8/16/2012

New York, NY, August 16, 2012 JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust (HCT), announced today that it has finalized a grant in the area of islet cell encapsulation to Dr. Camillo Ricordi, M.D. and a team of investigators at the Diabetes Research Institute (DRI), based at the University of Miami (FL).

Performed at the DRI since the 1980s, successful islet cell transplants give patients with type 1 diabetes (T1D) the ability to naturally produce their own insulin and lead healthier, more independent lives. However, only a small number of patients benefit from the procedure because of a shortage of cadaver islets, problems associated with the need for chronic immunosuppression drugs, and the low survival rate of islets immediately following implantation. The current transplant site, the liver, can be particularly inhospitable for newly implanted islets, leading to hypoxia (low oxygen) and inflammation. The number of transplants available to patients is also limited by the small number of donors and the large number of cells required for each procedure.

In the $4.6 million grant proposal being funded jointly by the JDRF-Helmsley Charitable Trust over three years, Dr. Ricordi's team will attempt to address the limitations of the requirements for immunosuppression, and the poor viability of islets, beginning with an alternate site of implantation. While the research community is exploring multiple possible alternatives, the DRI has chosen to pursue a fold in the lining of the abdomen called the omentum that the team believes will allow better access for the procedure, offer more space to accommodate delivery systems, and provide a safer environment for the newly-implanted cells.

"This is a critically important and timely support that will allow our team to remain focused on the path to a biologic cure for diabetes," Dr. Ricordi said. "The overall goal is to use a multipronged approach to address and resolve all of the outstanding issues in islet transplantation and move the field to the next level of success."

The other problem that Dr. Ricordi's team is attempting to solve is protecting the implanted cells from the body's immune response. Their approach to immunoprotection is two-fold. They will use a bioactive scaffold as a delivery system for the implanted islets that is designed to protect them from the immediate immune response. The scaffold allows the islet cells access to the surrounding blood vessels to prevent poor oxygenation, which will allow better regulation of blood sugar levels. The team is also engineering a conformal coating to encapsulate each islet to further promote long-term survival. Ultimately, the scaffold could be used to modify the immune cells in the implant local area, offering maximum protection. If successful, such technologies could remove the need for immunosuppression drugs and ensure long-term survival for the implanted cells.

"We are very excited to be supporting Dr. Ricordi's lab for this research," said JDRF Chief Scientific Officer Dr. Richard Insel. "Dr. Ricordi and colleagues have been pioneers in the area of islet cell transplantation and encapsulation, and we feel that they are well-positioned to advance an area that we hope will bring a real benefit to individuals with type 1 diabetes."


'/>"/>
Contact: Michael Cook
mcook@jdrf.org
212-479-7510
JDRF
Source:Eurekalert

Related medicine news :

1. Clemson researcher awarded nearly $245,000 to study automation trust and dependence
2. Dont Trust Dr. Google for Help on Infant Sleep Safety
3. Trust hormone oxytocin found at heart of rare genetic disorder
4. Why are elderly duped? UI researchers explain why
5. Mans Best Friend Points the Way in Genetic Research
6. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
7. By studying animal health, researchers find improved ways for developing, testing cancer therapies
8. Kolanowski earns GSAs 2012 Doris Schwartz Gerontological Nursing Research Award
9. Researchers aim to grow salivary glands using patients own cells
10. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
11. For young adults, appearance matters more than health, MU research suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: